-
FDA approves new vial size for CSL Behring immune treatment
KING OF PRUSSIA, Pa. — The Food and Drug Administration has approved a new vial size for a treatment for a rare immune system disorder.
CSL Behring announced the approval of a 10-g, or 50-mL, vial size for Hizentra (immune globulin subcutaneous [human]). The product is used to prevent infections in patients with primary immunodeficiency, and the new vial size will be available in October.
-
Upsher-Smith launches morphine sulfate capsules
MAPLE GROVE, Minn. — A new opioid painkiller drug made by Upsher-Smith Labs will become available on Wednesday, the drug maker said.
Upsher-Smith said it would launch its morphine sulfate extended-release capsules in the 10-mg, 20-mg, 30-mg, 50-mg, 60-mg, 80-mg and 100-mg strengths.
The company said its product would be the first generic entrant for the 10-mg extended-release capsule dosage strength, adding that there have historically been a limited number of morphine sulfate generics available.